24 results about "Heart output" patented technology

The invention discloses a monitoring method and system and a related device, which are applied to first electronic equipment, the first electronic equipment is provided with a first circuit, and the first circuit comprises a first electrode, a second electrode, a third electrode, a fourth electrode, an excitation current generation unit and a voltage measurement unit; receiving and responding to a first instruction, and determining that the first electrode and the second electrode are in good contact with skin through a first circuit; first information is determined through the first circuit, the first electrode makes contact with a first position of the user skin, the second electrode makes contact with a second position of the user skin, and the first position and the second position are located at the two ends of the thoracic cavity tissue respectively; and outputting first information, wherein the first information comprises one or more of the following items: cardiac output, stroke output, heart rate, ejection fraction and cardiac function judgment result. Therefore, the heart function condition of the user can be monitored in real time, and the user can conveniently monitor anytime and anywhere.

The invention relates to a non-invasive cardiac output function detection method and device, and belongs to the technical field of biological measurement. According to the method, on the basis of pulse wave related data, electrocardiowave related data and biological impedance and biological reactance related data which are obtained through detection, the bioelectrical impedance method is adopted to calculate and obtain the cardiac output of the bioelectrical impedance method, and the pulse wave method is adopted to calculate and obtain the cardiac output of the pulse wave method. And according to the impedance signal confidence coefficient and the pulse wave signal confidence coefficient, carrying out weighted average on the cardiac output of the bioelectrical impedance method and the cardiac output of the pulse wave method, and taking the weighted average as a cardiac output detection result. The detection device comprises a pulse wave detection system, an electrocardiogram detection system, a biological impedance and reactance detection system and a host used for data processing and result display. The reliability of cardiac output detection is remarkably improved while portability is guaranteed, and accurate, continuous and portable detection of non-invasive cardiac output is achieved.

Provided herein is a portable, handheld, non-invasive device for measuring and monitoring cardiac output in a subject. The device has a mouthpiece with a breath particle filter at the inlet on the device such that exhaled breath flows through the mouthpiece-filter into a chamber containing a CO2 meter and flow meter to measure CO2 concentration and volumetric breath flow. Measurements are sent as input data to a computer monitored by an operator whereupon an algorithm calculates cardiac output which is displayed or stored.

The present disclosure provides a fully integrated autonomous wearable ultrasound patch system (USoP) that includes a miniaturized flexible control circuit designed to interface with an array of ultrasound transducers for signal pre-processing and wireless data communication. Artificial intelligence (e.g., machine learning) may be used to track mobile organization targets and assist in data interpretation. In one implementation, USoP allows continuous tracking of physiological signals from tissue up to 164 mm deep. For moving subjects, USoP may continuously monitor physiological signals, including central blood pressure, heart rate, and cardiac output, for example for 12 hours. This result enables continuous autonomous monitoring of deep tissue signals.

According to the cardiac output measurement device according to the present disclosure, it is possible to measure the cardiac output more easily in a non-invasive manner by calculating the cardiac output based on the first ultrasound reception signal and the second ultrasound reception signal received from the first ultrasound probe and the second ultrasound probe that are located in both directions based on the heart.

The present invention relates to a control device, a ventricular assist system and an adaptive control method, which are intended to estimate the current flow of an LVAD based on the current current, calculate the target flow based on a flow preset value and heart rate compensation, and perform feedback adjustment to achieve adaptive changes in the current flow of the LVAD following changes in the heart rate; further, a target speed is set according to a speed preset value, heart rate compensation and flow compensation to reflect the followability of the target speed to the target flow, and the current speed is adjusted based on the target speed; an output adjustment current is calculated based on the difference between the target flow and the current flow, and the difference between the target speed and the current speed, to achieve nested closed-loop control of the speed and flow of the LVAD system, and ultimately the speed and flow will change synchronously with the gear change, thereby meeting the stability and accuracy requirements of cardiac output and speed.

The invention provides a non-invasive cardiac expulsion measuring method and system. The method comprises the following steps: inputting preprocessed arterial pressure waveform signals and basic vital sign data into a parameter estimation neural network for feature extraction, and outputting a correction factor cal, a scale factor SF and a waveform correction coefficient; respectively inputting the correction factor cal, the scale factor SF and the waveform correction coefficient into a pulse contour model, a LiDCO power model and a FloTrac standard deviation model for calculation to obtain a cardiac output estimated value CO1, a cardiac output estimated value CO2 and a cardiac output estimated value CO3; and fusing the cardiac output estimated value CO1, the cardiac output estimated value CO2 and the cardiac output estimated value CO3 by adopting a gradient lifting regression tree model, and outputting a final cardiac output value. According to the invention, calibration-free continuous monitoring is realized, and the stability and precision of cardiac output estimation are improved.

The application discloses a diving decompression sickness dynamic prediction and risk assessment system of multi-tissue parallel computation, relates to the fields of diving medicine, high-pressure medicine and human physiology modeling, and comprises a tissue unit planning module, a central blood circulation and coupling module and a model calculation and risk assessment module. The system divides a human body into a plurality of core physiological tissue units, and plans each tissue unit as a hybrid model composed of three sub-units of "fast-middle-slow". Then, the system simulates a human circulatory system by defining cardiac output, arterial blood inert gas partial pressure and dynamically distributing blood flow according to the tissue type, so as to construct a simulation model. Finally, according to the environmental pressure-time profile corresponding to a diving plan and the breathing gas composition, the simulation model is used to parallelly calculate the inert gas tension of all tissue units and sub-units, so as to be used for dynamic prediction and risk assessment of decompression sickness. The application provides a higher safety margin for saturation diving and repeated diving.

Compositions for improving metabolic function in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. S-beta-hydroxybutyrate in pure or enriched form provides energy to the heart, dilates the arteries, decreases blood pressure and systemic vascular resistance, and increases cardiac output. S-Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. S-Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and provide one or more electrolytes. S-Beta-hydroxybutyrate esters provide more controlled release without adding electrolytes. Compositions for improving heart function in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

The invention relates to the technical field of medical supplies, in particular to an ECMO arterial duct capable of changing the perfusion blood flow direction, which comprises a duct body with openings at two ends, the right end of the duct body is a pre-flushing section, the middle end of the duct body is a buffer section, and the left end of the duct body is a perfusion section; the perfusion section comprises a central tube cavity and three side tube cavities, the central tube cavity is formed in the middle end of the interior of the tube body, three equally-divided partition plates are arranged on the peripheral side of the central tube cavity, and the three partition plates divide the tube body into the three side tube cavities; and the inner wall of the left end of the side tube cavity is a blood flow redirection diversion curved surface. According to the invention, the arterial duct cavity is designed into the central lumen for forward blood flow and the three lateral lumens for variable-direction blood flow, so that the blood flow direction of the ECMO arterial duct is consistent with the physiological direction to the greatest extent, the adverse effect of ECMO on left heart output and the damage to vascular endothelium are weakened, and the treatment effect of the ECMO is improved. And the hemodynamic stability and safety in the VA-ECMO implementation process are improved.

1. Name of the product in this design: Graphical User Interface for Perioperative Monitoring Data Acquisition and Display of Electronic Equipment. 2. Intended use of this design: for use in an electronic device. 3. The key design features of this product are the graphical user interface displayed in the electronic device. 4. The image or photograph that best illustrates the design's key features: the front view. 5. The display screen panel adopts the conventional design, omitting the rear view, left view, right view, top view, and bottom view. 6. Purpose of the graphical user interface: This product design is used for monitoring data collection during the surgical period. 7. Human-computer interaction method of graphical user interface: The main view is the first interface; clicking "Data Hero" in the main view displays the change state diagram 1; clicking "OK" in the change state diagram 1 displays the change state diagram 2; clicking "Data Analysis" in the change state diagram 2 displays the change state diagram 3; clicking "Large View" at the bottom of the change state diagram 3 displays the change state diagram 4; clicking "Multi-parameter Time Series Plot" on the right side of the change state diagram 4 displays the change state diagram 5; clicking "Heart Rate-Systolic Blood Pressure Correlation Analysis" on the right side of the change state diagram 5 displays the change state diagram 6; clicking "HRV Analysis" on the right side of the change state diagram 6 displays the change state diagram 7; clicking "Cardiac Output-Mean Pressure Correlation Analysis" on the right side of the change state diagram 7 displays the change state diagram 8; clicking "AUC Analysis" on the right side of the change state diagram 8 displays the change state diagram 9; clicking "Event Log" at the bottom of the change state diagram 9 displays the change state diagram 9. Clicking "Record" displays status diagram 10; clicking "Collapse Drawer" at the top of status diagram 10 displays status diagram 11; clicking the gear icon in the lower left corner of status diagram 11 displays status diagram 12; clicking "Equipment Sorting" on the left side of status diagram 12 displays status diagram 13; clicking "Equipment Parameter Source" on the left side of status diagram 13 displays status diagram 14; clicking the head icon in the upper left corner of status diagram 14 displays status diagram 15; clicking "Pulse Oxygen Saturation Monitoring" in status diagram 15 displays status diagram 16; clicking "COHb" on the right side of status diagram 16 displays status diagram 17; clicking the red square stop button above status diagram 17 displays status diagram 18; clicking "OK" below status diagram 18 displays status diagram 19; scrolling down from status diagram 19 displays status diagram 20.

The invention provides a pet myocardial thickness data intelligent analysis and prediction early warning method and system, and relates to the technical field of pet medical image processing, and the method comprises the steps: employing Canny edge detection and a multi-feature constraint region growth algorithm to extract a myocardial boundary, employing orthogonal wavelet decomposition and reconstruction to optimize a myocardial contour, and achieving the sub-pixel precision myocardial thickness measurement; hilbert transform and a Bayesian network are utilized to predict and analyze the heart rate variability index, the cardiac output and the ventricular ejection fraction, and when the lesion risk probability exceeds a threshold value, early warning is triggered. According to the invention, the myocardial thickness measurement precision is improved, and early warning of heart diseases is realized.

Compositions for improving metabolic function in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. S-beta-hydroxybutyrate in pure or enriched form provides energy to the heart, dilates the arteries, decreases blood pressure and systemic vascular resistance, and increases cardiac output. S-Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. S-Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and provide one or more electrolytes. S-Beta-hydroxybutyrate esters provide more controlled release without adding electrolytes. Compositions for improving heart function in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

The utility model relates to the field of walking tests, in particular to a footpath mark monitoring device for a six-minute walking test, which comprises a test footpath and a movable guide rail, distance marks are arranged on the surface of the test footpath, the movable guide rail is arranged on one side of the test footpath, and a mark area is arranged on the other side of the test footpath. A moving seat is arranged at the upper end of the movable guide rail, guide sliding seats are fixedly mounted on the two sides of the lower end face of the moving seat and slidably connected with the upper end of the movable guide rail, and moving wheels are arranged on the two sides of the driving box; the non-invasive cardiac output monitor is additionally arranged, so that the motion state of a patient is synchronously recorded, hemodynamic parameters of the human body are continuously monitored in real time, the change of central functions in the resting, moving and motion processes is evaluated from the angle of hemodynamics, the test effect is improved, the movable guide rail is used for guiding, the movable seat synchronously follows to move, and the test efficiency is improved. And when the patient moves, the noninvasive cardiac output monitor is driven to move synchronously, so that the use of the monitor is facilitated.

The present disclosure provides a cardiac output determination method, device, electronic equipment and storage medium. The cardiac output determination comprises: acquiring echo energy data corresponding to N sampling moments determined at a predetermined blood vessel position in the process of cardiovascular circulation of microbubble ultrasound contrast agent in the cardiovascular system of a detection object; determining first power spectrum data corresponding to the N sampling moments according to the echo energy data corresponding to the N sampling moments respectively; determining a first power spectrum curve of the microbubble ultrasound contrast agent in the process of cardiovascular circulation according to the first power spectrum data corresponding to the N sampling moments respectively; determining an area characteristic parameter of the first power spectrum curve associated with a first circulation period of the microbubble ultrasound contrast agent in the process of cardiovascular circulation; and determining the cardiac output of the detection object based on the area characteristic parameter and a preset corresponding relationship.

The utility model discloses an ultrasound-based cardiac output measurement module and medical monitoring equipment, and the cardiac output measurement module comprises a module shell detachably connected to host equipment and a circuit board assembly arranged in the module shell, an ultrasonic probe interface and a signal transmission interface which are in communication connection with the circuit board assembly are embedded in the module shell, the ultrasonic probe interface is used for being connected with an ultrasonic probe, and the signal transmission interface is used for being in communication connection with a main processor in host equipment. The circuit board assembly comprises a parameter board used for controlling the ultrasonic probe to emit ultrasonic signals and obtaining cardiac output information according to returned ultrasonic echo signals. The cardiac output measurement module based on the ultrasound is inserted into the external installation space of the host shell in the form of an accessory module for use, the cardiac output measurement module based on the ultrasound is small in size, convenient to take and capable of being flexibly transferred, the whole equipment does not need to be pushed in the transferring process, and use is more convenient.

The invention relates to a system and method for determining heart performance. The systems and methods described herein determine metrics of heart performance via a mechanical circulation support device, and use the heart performance to calibrate, control, and deliver mechanical circulation support to the heart. The system includes a controller configured to operate the device, receive inputs indicative of device operating conditions and hemodynamic parameters, and determine vascular performance, including vascular resistance and compliance, and a native heart output. Systems and methods operate by using a mechanical circulation support device (e.g., a heart pump) to introduce controlled perturbations of the vascular system and in response to determine cardiac parameters (such as pulsation volume, vascular resistance and compliance, left ventricular end diastolic pressure) and ultimately the native heart output.

A cardiovascular monitoring system for measuring at least cardiac output comprises an implantable unit (2) configured for placement in a section of artery of a patient and a portable external unit (1) configured for mounting against or close to a patient's skin for bidirectional communication with the implantable unit. A cross-sectional area measurement sensor (8) includes at least one elastic conductive loop (15, 15a, 15b) and an electronic circuit (16) connected to the conductive loop configured to measure an inductance value of the conductive loop. At least one ultrasound transducer (7,11) is further configured to measure a velocity of blood flow based on a Doppler effect.

A system and method are provided for increasing cardiac output and improving perfusion of a patient's heart by intermittently occluding the patient's venous vasculature to unload the heart. The system may include first and second balloon catheters, which are selectively actuated to intermittently occlude the first and second veins to increase venous vascular resistance in the patient's lower and upper extremities, thereby selectively reducing arterial blood flow to the lower and upper extremities while maintaining arterial vascular resistance in the patient's heart and central organs and increasing perfusion to the patient's heart and central organs.

The invention provides a continuous cardiac output prediction method and system based on transfer learning. The method comprises the following steps: constructing a CCO prediction network model based on transfer learning; a two-stage transfer learning strategy is adopted to train a model, TCO (Intermittent Time Correction) regression transition is conducted to CCO monitoring, basic physiological parameters, MAP waveform features, depth time sequence features and individual specificity features are integrated, long-time dependence and local mutation features are captured through a TCN network, and the CCO monitoring accuracy is improved. The attention weighted fusion strategy dynamically optimizes the feature contribution, so that the model can comprehensively learn the hemodynamic law, the predicted Pearson's correlation coefficient R is greater than or equal to 0.96, and the percentage error PE is less than or equal to 12%; according to the method, a domain adaptive loss function is introduced to effectively reduce the domain difference between a public data set and a private data set, and smooth transition from intermittent prediction to continuous prediction is ensured by capturing a sequential relationship.

Various methods and compositions for treating single ventricle heart disease (SVHD) patients, including patients who have undergone Fontan surgery and who have Fontan circulation (Fontan patient), to improve exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in the SVHD patients, including the Fontan patients, using udenafil compositions.In one exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan, to improve the ventricular performance of the SVHD patient's, including the Fontan patient's, single functioning ventricle.In another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, MPI.In still another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, cardiac output.In yet another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, who is about 6 years of age or older, to improve at least one or more or all of the following in the SVHD patient, including the Fontan patient: (a) ventricular performance of the SVHD patient's, including a Fontan patient's, single functioning ventricle as measured by MPI; (b) exercise capacity as measured by oxygen consumption at anaerobic threshold (VAT); (c) exercise capacity as measured by oxygen consumption at maximal effort or max VO2; (d) work rate at VAT; (e) VE / VCO2 at VAT; diastolic blood pressure at rest; and (g) oxygen saturation (%) at rest.

Through biological signal data analysis, heart rate variability information is found and represented on log-log axes, a quartic function is set for a waveform resulting from analysis of the information, and one of two types of gradient values obtained based on different criteria, i.e., a gradient (GI) between points of inflection and a gradient (GT) of a tangent at a point of inflection (a GI value and a GT value), is employed as a final analysis result, depending on the number of extreme values in the quartic function. A cardiac output influenced by two factors, i.e., nervous system regulation which influences a heart rate and an arterial blood pressure which influences a stroke volume, undergoes increases / decreases due to the respective two factors. However, owing to the employment of one of the GI value and the GT value, an increase / decrease in the influence of each of these two factors is reflected.

A device comprising: a catheter or implanted device having a tip configured to be located within the distal JVC, between the confluence of the common iliac veins and the testicular / ovarian veins; and a flow restriction mechanism at or near the tip of the catheter or implanted device configured to be inflated with fluid or gas, and deflated by a control unit in order to optimize cardiac preload and cardiac output.

1. The name of the design product: non-invasive cardiac output monitor. 2. The use of the design product: for non-invasive monitoring of human cardiac output. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.